Kassab Asmaa E
Department of Pharmaceutical Organic Chemistry, Faculty of Pharmacy, Cairo University, Cairo, Egypt.
Arch Pharm (Weinheim). 2023 Jan;356(1):e2200424. doi: 10.1002/ardp.202200424. Epub 2022 Oct 3.
The pyrazolo[3,4-d]pyrimidine core has received a lot of interest from the medicinal chemistry community as a promising framework for drug design and discovery. It is an isostere of the adenine ring of adenosine triphosphate, which allows it to mimic kinase active site hinge region binding contacts. This scaffold has a wide pharmacological and biological value, one of which is as an anticancer agent. Many successful anticancer medicines have been designed and synthesized using pyrazolo[3,4-d]pyrimidine as a key pharmacophore. The main synthetic routes of pyrazolo[3,4-d]pyrimidines as well as their recent developments as promising anticancer agents acting as endothelial growth factor receptors and vascular endothelial growth factor receptor inhibitors, published in the time frame from 1999 to 2022, are summarized in this review to set the direction for the design and synthesis of novel pyrazolo[3,4-d]pyrimidine derivatives for clinical deployment in cancer treatment.
作为药物设计与发现的一个有前景的框架,吡唑并[3,4-d]嘧啶核心受到了药物化学界的广泛关注。它是三磷酸腺苷腺嘌呤环的电子等排体,能够模拟激酶活性位点铰链区的结合接触。该骨架具有广泛的药理和生物学价值,其中之一是作为抗癌剂。许多成功的抗癌药物已以吡唑并[3,4-d]嘧啶作为关键药效团进行设计和合成。本文综述了1999年至2022年期间发表的吡唑并[3,4-d]嘧啶的主要合成路线及其作为有前景的抗癌剂(充当内皮生长因子受体和血管内皮生长因子受体抑制剂)的最新进展,为设计和合成用于癌症治疗临床应用的新型吡唑并[3,4-d]嘧啶衍生物指明方向。